Bladder cancer

molecular determinants of personalized therapy

Antonio Lopez-Beltran, Matteo Santoni, Francesco Massari, Chiara Ciccarese, Giampaolo Tortora, Liang Cheng, Holger Moch, Marina Scarpelli, Carlos Reymundo, Rodolfo Montironi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.

Original languageEnglish (US)
Pages (from-to)115-124
Number of pages10
JournalCurrent Drug Targets
Volume16
Issue number2
StatePublished - 2015

Fingerprint

Urinary Bladder Neoplasms
Tumors
Genes
Receptor, Fibroblast Growth Factor, Type 3
Molecular biology
Oncology
Taxonomies
Molecular Biology
Complementary DNA
Technology
Mutation
p53 Genes
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lopez-Beltran, A., Santoni, M., Massari, F., Ciccarese, C., Tortora, G., Cheng, L., ... Montironi, R. (2015). Bladder cancer: molecular determinants of personalized therapy. Current Drug Targets, 16(2), 115-124.

Bladder cancer : molecular determinants of personalized therapy. / Lopez-Beltran, Antonio; Santoni, Matteo; Massari, Francesco; Ciccarese, Chiara; Tortora, Giampaolo; Cheng, Liang; Moch, Holger; Scarpelli, Marina; Reymundo, Carlos; Montironi, Rodolfo.

In: Current Drug Targets, Vol. 16, No. 2, 2015, p. 115-124.

Research output: Contribution to journalArticle

Lopez-Beltran, A, Santoni, M, Massari, F, Ciccarese, C, Tortora, G, Cheng, L, Moch, H, Scarpelli, M, Reymundo, C & Montironi, R 2015, 'Bladder cancer: molecular determinants of personalized therapy', Current Drug Targets, vol. 16, no. 2, pp. 115-124.
Lopez-Beltran A, Santoni M, Massari F, Ciccarese C, Tortora G, Cheng L et al. Bladder cancer: molecular determinants of personalized therapy. Current Drug Targets. 2015;16(2):115-124.
Lopez-Beltran, Antonio ; Santoni, Matteo ; Massari, Francesco ; Ciccarese, Chiara ; Tortora, Giampaolo ; Cheng, Liang ; Moch, Holger ; Scarpelli, Marina ; Reymundo, Carlos ; Montironi, Rodolfo. / Bladder cancer : molecular determinants of personalized therapy. In: Current Drug Targets. 2015 ; Vol. 16, No. 2. pp. 115-124.
@article{96fd80d0272545b3b6ac6c53f9b546ce,
title = "Bladder cancer: molecular determinants of personalized therapy",
abstract = "Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.",
author = "Antonio Lopez-Beltran and Matteo Santoni and Francesco Massari and Chiara Ciccarese and Giampaolo Tortora and Liang Cheng and Holger Moch and Marina Scarpelli and Carlos Reymundo and Rodolfo Montironi",
year = "2015",
language = "English (US)",
volume = "16",
pages = "115--124",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Bladder cancer

T2 - molecular determinants of personalized therapy

AU - Lopez-Beltran, Antonio

AU - Santoni, Matteo

AU - Massari, Francesco

AU - Ciccarese, Chiara

AU - Tortora, Giampaolo

AU - Cheng, Liang

AU - Moch, Holger

AU - Scarpelli, Marina

AU - Reymundo, Carlos

AU - Montironi, Rodolfo

PY - 2015

Y1 - 2015

N2 - Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.

AB - Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer. All these changes are behind the use of non-traditional approach to therapy of bladder cancer patients and are ready to change our daily practice of uro-oncology. The observed correlation of some molecular alterations with tumor behavior and the identification of their targets at cellular level might support the use of molecular changes together with morphological data to develop new clinical and biological strategies to manage patients with urothelial cancer. The current review provides comprehensive data to support personalized therapy for bladder cancer based on an integrated approach including pathologic and clinical features and molecular biology.

UR - http://www.scopus.com/inward/record.url?scp=84924292913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924292913&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 115

EP - 124

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -